Syngene International Limited — PPTs, 30-04-2026: Investor Presentation

Syngene reported modest revenue growth, up 2% YoY to Rs 1,037 Cr in Q4 FY26 and 3% YoY to Rs 3,739 Cr for the full year. However, PAT before exceptional items declined 16% to Rs 153 Cr in Q4 and 20% to Rs 380 Cr for FY26, with margins also facing pressure.

**Growth & Strategy:** Syngene is focused on expanding its integrated drug discovery, development, and manufacturing services, particularly in advanced Antibody-Drug Conjugates (ADCs). Their strategy emphasizes operational excellence and building a comprehensive, one-stop-shop for biologics, spanning from discovery to commercial production.

**Recent Developments:** The company operationalized its ADC discovery lab, creating end-to-end ADC capabilities. It also achieved GCP-NABL accreditation and was recognized in the S&P Global Sustainability Yearbook 2026. Significant management changes include Kiran Mazumdar-Shaw transitioning to Executive Chairperson, and Siddharth Mittal appointed MD & CEO from July 1, 2026.

**Outlook:** Management plans to prioritize operational excellence and enhance integrated end-to-end therapeutic discovery services, especially for large molecules, reinforcing its commitment to ESG for long-term value creation.